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Abstract
Background: Diazoxide is the first-line treatment for pediat-
ric hyperinsulinemic hypoglycemia (HI). This study aimed to 
elucidate the pharmacokinetics of diazoxide in children with 
HI. Methods: We obtained 81 blood samples from 22 chil-
dren with HI. Measured serum diazoxide concentrations 
were used for population pharmacokinetic analysis. Patient 
factors influencing pharmacokinetics were estimated using 
nonlinear mixed-effects model analysis. Relationships be-
tween drug exposure and adverse drug reactions were also 
investigated. Results: Diazoxide disposition in the body was 
described by a 1-compartment model. Oral clearance (CL/F) 
and the volume of distribution were proportional to body 
weight (WT), as expressed by CL/F in males (liters/h) = 
0.0358 + 0.00374 × WT (kg). CL/F in females was 39% greater 
than that in males. Steady-state concentrations of diazoxide 
were similar following twice- and 3 times-daily dosing when 
the total daily doses were comparable. A patient whose se-
rum diazoxide concentration exceeded 100 μg/mL over a 
4-month period developed hyperglycemia. No significant 
correlation was observed between severity of hirsutism and 
diazoxide concentration. Conclusion: We have proposed for 
the first time a population pharmacokinetic model for di-
azoxide in children with HI. The potential risk of diabetes 
mellitus and/or hyperglycemia increases when serum con-
centrations of diazoxide exceed 100 μg/mL.
© 2017 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Hyperinsulinemic hypoglycemia (HI) [1–4], charac-
terized by profound hypoglycemia due to inappropriate 
insulin secretion, is the most common cause of persistent 
hypoglycemia in children. Poor control of blood glucose 
levels in children with HI can result in neurological se-
quelae, including mental retardation and epilepsy. 
Diazoxide raises blood glucose concentrations by sup-
pressing insulin secretion, and this agent is the first choice 
for treating children with HI, although diazoxide is 
thought to be effective in infantile-onset HI only, and not 
in neonatal HI [3]. Diazoxide binds to the sulfonylurea 
receptor 1 subunit and inhibits closure of the ATP-sensi-
tive potassium channel with subsequent diminished insu-
lin secretion by pancreatic β cells. In Japan, the starting 
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dose of diazoxide administered to children with HI is 5–10 
mg/kg/day before the age of 1 year, and 3–5 mg/kg/day 
thereafter [5]. This dosage regimen was determined from 
clinical experience worldwide, and is not based on evi-
dence for optimal use [6].
The aim of this study was to elucidate the pharmaco-
kinetics of diazoxide in children with HI by population 
pharmacokinetic (PPK) analysis [7–11] using nonlinear 
mixed-effects modeling (NONMEM) [12] methods. Up 
to now, the pharmacokinetics of diazoxide have been re-
ported from only 4 adults [13, 14] and 4 children [14], 
yielding insufficient information considering this agent is 
used as a first-line treatment for HI in children. PPK anal-
ysis is recommended by the FDA in the US and the Phar-
maceuticals and Medical Devices Agency (PMDA) in Ja-
pan as a useful method for assessing special populations 
such as pediatric and geriatric patients, and patients with 
complicated organ diseases [15, 16], as it can analyze 
pharmacokinetic features using sparsely sampled data 
which is more feasible in clinical settings [12].
We also investigated relationships between drug expo-
sure and responses, including adverse reactions and phar-
macological surrogates. The most common adverse 
events related to diazoxide include edema and hirsutism 
[6], with the latter occurring prominently in children, 
sometimes leading to discontinuation of the drug.
Subjects and Methods
Patients
Children newly or already diagnosed with HI and being treated 
with diazoxide (Proglycem; Schering-Plough, NJ, USA) were re-
cruited prospectively from a multicenter study group for this in-
vestigation from July 2004 to July 2007 in Japan. Compliance was 
determined by questionnaire to the parent(s) or attending doctors. 
The exclusion criteria of this study were poor compliance, forget-
ting to take diazoxide on the day before blood sampling, patients 
older than 20 years of age, and co-treatment with corticosteroids 
or growth hormone.
The present study was approved by the Ethics Committee, Keio 
University Hospital, and written informed consent was obtained 
from the parent(s) of all enrolled patients.
Treatment
The physicians-in-charge determined the dosage regimen for 
each patient. When the patients received diazoxide at the same 
dose for longer than 1 week, serum diazoxide concentrations were 
considered to be at steady state, based on the reported half-life of 
diazoxide of 28 ± 8.3 h in adults [17] and steady state being theo-
retically reached after 5 times the half-life [18].
Blood Sampling
Blood samples were obtained for the measurement of serum 
diazoxide concentrations and for routine laboratory testing (e.g., 
total cell counts and blood chemistry). For the PPK analysis, 
parent(s) or physicians recorded the exact times of administration 
of diazoxide or blood sampling, respectively.
Serum Diazoxide Assay
Serum diazoxide concentrations were measured according to a 
previously reported method, with minor modifications [19–21]. 
Diazoxide and phenacetin, used as an internal standard, were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA) and Wako 
Pure Chemical Industries, Ltd. (Osaka, Japan), respectively. Quan-
titation of diazoxide was carried out using high-performance liq-
uid chromatography (HPLC) with ultraviolet detection. After sep-
aration of the serum by centrifugation, the samples were stored at 
−20  ° C.
For the diazoxide assay, serum aliquots of 100 μL were mixed 
with 50 μL of 200 μg/mL phenacetin. Proteins were precipitated by 
adding 400 μL of 0.33 M perchloric acid solution and 50 μL of 50% 
methanol (MeOH). Samples were then vortexed (20 s) and centri-
fuged (12,000 rpm, 20 min, 5  ° C), and 20 μL of the supernatant was 
injected onto the HPLC system.
Chromatographic separation was carried out at a flow rate of 
1 mL/min with a binary mobile phase consisting of 0.01 M 1-pen-
tanesulfonic acid sodium salt solution with 0.1% (v/v) acetic acid 
and MeOH. The following step gradient profile was used for 
HPLC: 40% MeOH for 7.5 min, increasing up to 95% MeOH over 
2.5 min, isocratic at 95% MeOH for 7 min, decreasing to 40% 
MeOH within 0.01 min, and remaining constant until the end of 
the run. Diazoxide and the internal standard were separated using 
an Inertsil ODS-3 column (5 μm, 4.6 × 150 mm; GL Sciences, To-
kyo, Japan), maintained at 40  ° C and then detected, respectively, 
at 270 nm. The retention times of diazoxide and the internal stan-
dard were 6.0 and 9.0 min, simultaneously. Standard curves for 
serum diazoxide concentration were linear within the range from 
0.5 to 200 μg/mL, with the lower limit of detection being 0.5 μg/
mL. The inter- and intraday variability in accuracy (expressed as 
relative error) for the diazoxide assay was 2.0% (0.51 μg/mL) and 
−0.6% (202.3 μg/mL), and 2.0% (0.51 μg/mL) and 0.4% (202.3 μg/
mL), respectively. The inter- and intraday variability in precision 
(expressed as the coefficient of variation) was 1.9% (0.51 μg/mL) 
and 0.7% (202.3 μg/mL), and 1.9% (0.51 μg/mL) and 0.7% (202.3 
μg/mL), respectively. The recovery of added diazoxide standards 
to serum was 78.3 ± 3.3% (0.5 μg/mL) and 80.4 ± 0.9% (200 μg/
mL).
PPK Analysis of Diazoxide
Pharmacokinetic Model
PPK analysis was performed using NONMEM 7.3.0 software 
with a PREDPP library [12]. The pharmacokinetics of diazoxide 
were assumed to adhere to a 1-compartment model with first-or-
der elimination from the central compartment [14]. The struc-
tural parameters were total body clearance (CL/F, in which F rep-
resents oral bioavailability) and volume of distribution in the cen-
tral compartment (V/F). CL/F and V/F were estimated using a 
model from the PREDPP library (ADVAN2, TRANS2), represent-
ed as follows:
C = F × D × ka/V × (ka-ke) × {exp(-ke × t)-exp(-ka × t)},
CL = V×ke,
where C denotes the concentration of the drug in the serum, D 
represents dose (mg), ka is the first-order absorption rate constant, 
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ke is the first-order elimination rate constant derived as CL/V, and 
t is time after dose (h).
The interindividual variability in CL/F and in V/F was assumed 
to obey a log-normal distribution, expressed by the following 
equations:
lnCLi = lnCL + ηCLi,
lnVi = lnV + ηVi,
where ηi denotes the difference between the individual parameters 
(CLi, Vi) for subject i and the typical values of CL and V predicted 
by the population mean. The η is distributed with a mean of zero 
and a variance equal to ω2. The addition of ω on ka resulted in 
model instability, and thus, ω for ka was not included in our pop-
ulation model.
The residual variability of concentrations includes drug assay 
error, intraindividual variability, and deviations caused by model 
misspecification, and is described by the log-normal distribution 
model:
lnCi,j = lni,j + εi,j,
where Ci,j and i,j are the observed and predicted diazoxide concen-
trations, respectively, at time ti for a subject j. εi,j represents inde-
pendent, identically distributed random errors with mean zero 
and variance σ2 for serum concentrations.
Factors Affecting the Pharmacokinetics of Diazoxide
Covariates that could influence the pharmacokinetics of di-
azoxide were added one by one in a stepwise fashion to the basic 
model without any covariates. The individual post hoc estimates 
of diazoxide CL/F were obtained from the basic model before add-
ing a covariate, and a linear relationship between diazoxide CL/F 
and body weight (WT) (kg) was observed. In the same way, a linear 
relationship was also observed between diazoxide V/F and WT. 
Age was a confounding variable which correlated to WT. As the 
dose of diazoxide was determined conventionally based on WT, 
we incorporated this as a fixed-effect variable into the basic model. 
For each model, the improvement in fit obtained on adding a 
fixed-effect variable into the base model was assessed by the differ-
ence in objective function, which is equivalent to −2(log-likeli-
hood difference). This difference in the value of the objective func-
tion (−2 log-likelihood difference) is asymptotically distributed as 
χ2 with degrees of freedom equal to the number of added/reduced 
parameters. A change in the objective function value of 3.841 with 
the degrees of freedom equal to 1 indicated statistical significance 
(p < 0.05). We examined several potential covariates (age, gender, 
concomitant use of antiepileptic drugs, and severity of HI) which 
could affect CL/F or V/F. Thereafter, a final population model was 
obtained by including all significant covariates, and the final PPK 
parameters were estimated. 
Model Validation
The PPK parameters and the final model obtained in the above 
analysis were qualified by the following methods.
Diagnostic analyses compared the observed serum diazoxide 
concentrations and the individually predicted concentrations us-
ing Bayesian estimation. The stability and robustness of the final 
model were assessed by a bootstrap validation [22, 23], which in-
volved taking 200 datasets constructed by resampling from the 
original dataset, and fitting the final model repeatedly to these da-
tasets to obtain the PPK parameters. The median and 5th and 95th 
percentiles of 200 parameter estimates obtained from successful 
bootstrap replicates were compared to the final parameter esti-
mates from the original dataset.
Effect of Divided Doses per Day
The Bayesian method was employed to estimate individual 
pharmacokinetic parameters using measured serum diazoxide 
concentrations and the final PPK parameters. The elimination 
half-life (T1/2) and the predicted average serum concentration at 
steady state (Css,av) were calculated by the following equations:
T1/2 = 0.693V/CL,
Css,av = F × D/(CL × τ),
where τ represents the dosing interval (h).
To investigate the effect of divided doses per day, we compared 
the simulated Css,av values between patients treated twice a day 
with oral diazoxide (twice-daily group) and those treated 3 times 
a day (3 times-daily group). For this simulation, we assumed 12 
and 8 h, respectively, as dosing intervals. Furthermore, entire se-
rum diazoxide concentration time profiles were simulated for a 
typical patient (male, 20 kg WT) treated with 7.5 mg/kg/day di-
azoxide orally at different time intervals during the day.
Exposure and Response (Efficacy and Adverse Drug Reactions) 
Analysis
Each physician-in-charge evaluated the following 4 items sub-
jectively and categorized them into 3–5 groups: (1) efficacy of di-
azoxide in blood glucose control (5 groups; very effective, effective, 
slightly effective, ineffective, and the data could not be obtained), 
(2) the severity of HI as evaluated based on the hypoglycemic con-
dition (3 groups; mild, moderate, severe), (3) edema (3 groups: 
none, transient, permanent), and (4) hirsutism (4 groups: none, 
mild, moderate, and severe), according to the physician’s global 
assessment. Hirsutism was evaluated in selected patients who were 
treated with the same dose of diazoxide for more than 1 month.
Statistical Analysis
StatcelTM version 2 was used for statistical analysis. The non-
parametric Mann-Whitney U test was used to compare differenc-
es in Css,av between the twice- and 3 times-daily groups, and the 
Kruskal-Wallis test was used to compare differences in Css,av 
among 4 groups, scaled for hirsutism. A p value of less than 0.05 
was considered statistically significant.
Results
Patients and Data
Of the 23 pediatric patients enrolled in this study, 1 
patient was diagnosed as having Turner syndrome and 
received growth hormone therapy. We excluded this sub-
ject as growth hormone therapy influences blood glucose 
levels, and this could have affected the evaluation of di-
azoxide efficacy. Therefore, we performed population 
pharmacokinetic and pharmacodynamic analysis of di-
azoxide using serum concentration data from 81 samples 
taken from 22 patients. Table 1 summarizes the charac-
Kizu/Nishimura/Sato/Kosaki/Tanaka/
Tanigawara/Hasegawa
Horm Res Paediatr4
DOI: 10.1159/000478696
teristics of the 22 patients. Four patients were newly diag-
nosed with HI, and 18 patients had been diagnosed previ-
ously. Five patients received concomitant treatment with 
anticonvulsants such as carbamazepine, clobazam, val-
proic acid, phenobarbital, or zonisamide. Two patients 
were diagnosed with glutamate dehydrogenase deficien-
cy. Figure 1 shows the serum concentrations of diazoxide 
versus post-dose sampling times.
PPK of Diazoxide
Diazoxide disposition in the body was described by a 
1-compartment model. Both CL/F and V/F were de-
scribed proportional to WT. Table 2 details the univariate 
hypothesis testing for each factor that could have affected 
the pharmacokinetics of diazoxide. Gender and the sever-
ity of HI had a significant influence on CL/F, while nei-
ther concomitant antiepileptic drug administration nor 
age significantly influenced CL/F or V/F. In a subsequent 
multivariate analysis, gender difference was incorporated 
into the PPK model.
The final estimates for the PPK parameters of diazox-
ide are summarized in Table 3. CL/F in females was 1.4 
times greater than that in males. The estimated interindi-
vidual variability in CL/F and V/F was 37.3 and 49.3%, 
respectively, and the intraindividual residual variability 
for diazoxide concentration was 20.1%.
The obtained pharmacokinetic model and its param-
eters were qualified by diagnostic analyses and a boot-
strap validation. Comparison of the observed versus pre-
dicted values revealed no systematic bias in the prediction 
of plasma concentrations (online suppl. Fig. 1a; see www.
karger.com/doi/10.1159/000478696 for all online suppl. 
material), while the weighted residuals were uniformly 
scattered around the horizontal axis of zero (online suppl. 
Fig. 1b). The final model was then fitted repeatedly to 200 
bootstrap-resampled datasets, and all 200 were success-
fully converged. The medians of the parameter estimates 
obtained from the bootstrap analyses were comparable to 
the final parameter estimates obtained from the original 
Number Median Rangea
Patients 22
Serum samples 81
Serum samples/patient 3 1–13
Gender (male/female) 17/5
Age, years 4.3 0.1–15.2
Weight, kg 17.5 3.5–70.6
Serum creatinine, mg/dL 0.3 0.1–0.47
Daily diazoxide dose, mg/kg/day 6.7 2.3–15.1
Divided doses per day
(once/ twice/3 times/4 times)
1/10/10/1
Severity (mild/moderate/severe)b 3/10/9
Concomitant antiepileptic drugs (yes/no) 5/17
Treatment period with diazoxide, years 3.5 (1st time – 
11.25) 
a  Minimum–maximum values. b  Severity classification for male patients: 1 mild, 8 
moderate, and 8 severe disease.
Table 1. Characteristics of the patients 
who participated in the present study
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Fig. 1. Diazoxide concentrations in serum vs. post-dose sampling 
time. The closed circles represent the observed values in patient 13 
who developed hyperglycemia, and the open circles represent all 
other patients.
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dataset (online suppl. Table 1). Some parameters (θ2, θ4, 
θ5, ω) showed large confidence intervals due to the small 
number of subjects.
Effect of Divided Doses per Day
Individual pharmacokinetic parameters were estimat-
ed using the PPK parameters and observed diazoxide 
concentrations for each patient by the Bayesian algo-
rithm. The T1/2 of diazoxide was estimated to be 15 ± 
5.3 h (range: 5.9–27.7). The predicted average serum con-
centration at steady state (Css,av) of diazoxide correlates 
with diazoxide dose/kg/day (online suppl. Fig. 2).
There was no significant difference in Css,av between 
the twice- and 3 times-daily groups (Fig.  2b). These 2 
groups were not significantly different in terms of the 
male/female ratio, concomitant antiepileptic drug use, 
and daily diazoxide dose (6.0 ± 2.3 mg/kg/day in the 
twice-daily group and 7.8 ± 4.0 in the 3 times-daily group), 
while there was a significant difference in age: 8.0 ± 4.1 
years in the twice-daily group and 2.3 ± 2.3 years in the 3 
times-daily group.
Time courses of serum diazoxide concentration result-
ing from different dosing regimens, with specific dosing 
intervals per day, were simulated over 96 h (Fig.  2a). 
Once-daily dosing resulted in a large difference com-
pared to the other regimens; however, virtually no dif-
ference was seen between the twice- and 3 times-daily 
regimens. Therefore, the pharmacokinetic simulations 
revealed that the steady-state concentrations of diazoxide 
are similar with respect to twice- and 3 times-daily dosing 
as long as the total daily doses are comparable.
Pharmacokinetics/Pharmacodynamics of Diazoxide
Diazoxide was considered very effective in controlling 
blood glucose levels in 7 patients; it was effective in 14 
patients, and its efficacy could not be evaluated in 1 pa-
tient.
The Css,av of 1 patient who suffered permanent edema 
and who did not receive diuretic treatment was 70.2 μg/
mL, while that of the other 3 patients who had recovered 
from edema, 2 of whom were administered diuretics, 
ranged from 42.3 to 120.7 μg/mL. Diazoxide was not dis-
continued in any of these 4 patients. We were not able to 
analyze the correlation between Css,av and edema statisti-
cally, as the edema was permanent in only 1 patient, and 
transient in the other 3 patients. There was no significant 
Factor OBJ ∆ OBJ p valuea
Basic model 450.165
Gender on CL/F 444.472 5.693 <0.025
Concomitant antiepileptic drugs on CL/F 449.367 0.798 ns
Age on CL/F 449.642 0.523 ns
Severity of HI on CL/F 433.035 17.130 <0.005
Gender on V/F 449.885 0.280 ns
Concomitant antiepileptic drugs on V/F 449.571 0.594 ns
Age on V/F 449.570 0.595 ns
Severity of HI on V/F 449.951 0.214 ns
OBJ, objective function values. HI, hyperinsulinemic hypoglycemia; CL/F, total body 
clearance (in which F represents oral bioavailability); V/F, volume of distribution in the 
central compartment; ns, not statistically significant. a Significance criterion: ∆ OBJ(–2 
log-likelihood difference) >3.841, p < 0.05.
Table 2. Hypothesis testing for factors 
affecting pharmacokinetics of diazoxide
Table 3. Population pharmacokinetic model and parameter 
estimates of diazoxide in children with hyperinsulinemic 
hypoglycemia
Clearance (CL/F), L/h
Male
Female
0.0358+0.00374 × WT
0.0498+0.00520 × WT
Distribution volume (V/F), L 1.37+0.0459 × WT
Absorption rate constant (Ka), 1/h 0.596
Interindividual variability
ωCL2
ωv2
0.139 (37.3% CV)
0.243 (49.3% CV)
Intraindividual variability (δ2) 0.0406 (20.1% CV)
 CL ratio of female/male = 1.39. CL/F, total body clearance (in 
which F represents oral bioavailability); V/F, volume of distribution 
in the central compartment; WT, body weight (kg); CV, coefficient 
of variation.
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correlation between the estimated Css,av and severity of 
hirsutism (shown in Fig. 3), while online supplementary 
Figure 3 shows no influence of the treatment period.
It is of note that 1 patient developed hyperglycemia. 
This patient was administered excessively high doses of di-
azoxide for a long period, in order to prevent hypoglyce-
mia on days he was sick due to a short fasting duration and 
repeated moderate early morning hypoglycemia at the age 
of 2.5 years. The diazoxide concentration was 128.5 μg/mL 
at a dose of 14 mg/kg/day, while the nonfasting blood glu-
cose level was 104 mg/dL, and HbA1c was measured as 
6.6% (National Glycohemoglobin Standardization Pro-
gram, NGSP) (Table 4). The concentration of diazoxide 
was further elevated to 158.4 μg/mL at a dose of 18 mg/kg/
day, and this patient was diagnosed with diabetes mellitus 
based on a blood glucose level of 212 mg/dL and an HbA1c 
measurement of 6.8%. The level of HbA1c returned to nor-
mal when the diazoxide dose was reduced to 14 mg/kg/day. 
No fatal adverse event was reported in this study.
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Fig. 2. Simulated serum concentration profiles of diazoxide in chil-
dren according to the obtained population pharmacokinetic pa-
rameters. a Simulated serum concentration profiles of diazoxide 
(from the first dose to 96 h) in a typical male patient treated with 
oral diazoxide at a dose of 7.5 mg/kg/day with differently divided 
doses per day. The solid, broken, and dotted lines represent 
3 times-, twice-, and once-daily administration, respectively. 
b Steady-state average concentration of diazoxide in serum (Css,av) 
for 20 subjects. The Css,av was 44.6 ± 13.0 μg/mL for the twice- 
daily dosing group (n = 10) and 43.1 ± 32.1 μg/mL for the 3 
times-daily dosing group (n = 10). There was no statistically sig-
nificant difference between the 2 groups.
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Fig. 3. Relationship between the steady-state average concentra-
tion of diazoxide in serum and diazoxide dose vs. severity of 
hirsutism. Hirsutism could be evaluated in 18 patients. The open 
circles, triangles, and crosses represent moderate, mild, and no 
hirsutism, respectively.
Table 4. Laboratory data of a patient who developed hyperglycemia 
(patient 13)
Diazoxide,
mg/kg/day
Serum 
concentration 
of diazoxide,
μg/mL
Blood 
glucose,
mg/dL
HbA1c
(NGSP),
%
At the first
measurement 14 86.3 123 5.8
At 1 month 14 108.7 100 6.1
At 2 months 14 114.9 103 5.6
At 3 months 14 128.5 104 6.6
At 4 months 18 158.4 212 6.8
NGSP, National Glycohemoglobin Standardization Program.
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Discussion
In this study, we elucidated the pharmacokinetics of 
diazoxide in children with HI for the first time using PPK 
analysis, resulting in novel findings regarding pharmaco-
kinetic parameters, covariates, model structure, the half-
life of diazoxide, and the effects of divided doses per day.
We found that WT had a significant influence on CL/F 
and V/F, although age had no influence. However, it is to 
be expected that age had no further effect on the pharma-
cokinetics of diazoxide, as WT is usually proportional to 
age during childhood, and we confirmed this proportion-
al relationship among the patients who participated in 
this study.
Gender difference and the severity of HI were found to 
be potential covariates with respect to CL/F (Table 2). The 
pharmacokinetics of diazoxide have been investigated 
previously in males, but females have not been studied, 
and gender difference has never been reported. The pres-
ent patient population included 5 females, and we found 
a gender difference in CL/F, with females showing a 39% 
greater CL/F than males. However, due to the lack of bal-
ance in the number of male and female patients here, fur-
ther study is needed to confirm gender difference. In a 
subsequent multivariate analysis, gender and the severity 
of HI were correlated, because when gender difference 
was incorporated as a covariate on CL/F, the severity ef-
fect disappeared, and vice versa. As the physicians’ evalu-
ation of severity was subjective and no predetermined cri-
teria existed, we did not accept the severity information 
as a final result of this analysis. Further studies are needed 
to investigate the potential contribution of gender differ-
ence and/or the severity of HI.
Concomitant use of antiepileptic drugs had no signifi-
cant influence on CL/F and V/F. We attributed this result 
to the different disposition pathways utilized by antiepi-
leptic drugs and diazoxide. Typically, antiepileptic drugs 
are metabolized by CYP450 in the liver, while diazoxide 
is excreted by the kidneys. Pruitt et al. [14] reported that 
the half-life of diazoxide was shorter in 2 children receiv-
ing phenobarbital and diphenylhydantoin, and attributed 
this to concomitant use of an antiepileptic agent. How-
ever, we suspect that confounding factor(s), such as WT, 
affected the outcome of this study.
Model validation also indicated the stability of the final 
model and the reliability of the parameter estimates (on-
line suppl. Fig. 1 and Table 1). However, we should keep 
in mind other potential factors that could bring about in-
ter- and intraindividual pharmacokinetic variability as-
sociated with diazoxide. There are unknown possibly in-
fluential covariates such as the pathogenic mechanisms 
related to HI and creatinine clearance. As HI is a clini-
cally and genetically heterogeneous disorder [1–6, 24], 
and diazoxide is excreted by the kidneys [13], renal func-
tion can be an important covariate candidate, although 
serum creatinine levels were normal in all of the patients 
who participated in this study.
The obtained half-life of diazoxide varied from 5.9 to 
27.7 h, which is consistent with previous reports citing 
9.5–24 h [14]. Our simulations indicated no significant 
difference in the Css,av between the twice- and 3 times-
daily dosing groups. The pharmacokinetic simulations 
also showed a similarity in the fluctuation of the diazox-
ide concentration between the twice a day and 3 times a 
day dosage regimens. In contrast, the fluctuation seen 
when the drug was given once daily was extremely large. 
Thus, divided dosing at twice per day is equally acceptable 
to dosing 3 times a day.
Two adverse events were notable in the patients stud-
ied here, hirsutism and diabetes mellitus. Hirsutism is 
one of the most common adverse events reported during 
diazoxide therapy, and it was apparent in this study in 16 
out of 18 analyzed cases. We did not find a significant cor-
relation between the severity of hirsutism and the con-
centration of diazoxide, suggesting that this adverse event 
could be independent of drug concentration. One patient 
(patient 13) developed diabetes mellitus, which we attri-
bute to diazoxide based on its pharmacological effects, the 
long-term high exposure to diazoxide (>100 μg/mL), and 
particularly, as his measured HbA1c of 6.8% was associ-
ated with a serum concentration of diazoxide of 158.4 μg/
mL, which was far higher than that observed in the other 
patients. Pruitt et al. [14] reported on a boy who experi-
enced hyperglycemia after receiving diazoxide at 30 mg/
kg/day for 4 days, and the concentration of diazoxide 
measured in the patient’s serum was 120 μg/mL. We spec-
ulate that a risk of diabetes mellitus and/or hyperglycemia 
may be increased when the serum concentration of di-
azoxide exceeds 100 μg/mL.
The limitations of this study are the small number of 
patients, the unbalanced number of male and female pa-
tients, the lack of predetermined criteria regarding the 
severity of HI, and the possibility that our study popula-
tion included some subjects with transient-type HI who 
had already been in spontaneous remission, leading to 
overestimation of the efficacy of diazoxide. Diazoxide 
was evaluated to be effective in all cases except for 1 pa-
tient. Measurement of 1,5-AG (1,5-anhydro-D-glucitol) 
before and after changing the diazoxide dose may provide 
additional efficacy information in future studies, as 1,5-
Kizu/Nishimura/Sato/Kosaki/Tanaka/
Tanigawara/Hasegawa
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AG reflects average blood glucose levels for a shorter pe-
riod than HbA1c.
In conclusion, we have proposed the first PPK model 
for diazoxide in children with HI. Steady-state concentra-
tions of diazoxide were similar between twice- and 3 
times-daily dosing as long as the total daily doses were 
comparable. It seems logical to use empirically deter-
mined doses and divided doses per day. However, the 
potential risk of diabetes mellitus and/or hyperglycemia 
increases when the serum concentration of diazoxide 
exceeds 100 μg/mL.
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